Testosterone Esters Compared: Which Timing Fits?
Which testosterone form fits the routine?
The ester changes release timing while the hormone released remains testosterone. Some products have weekly treatment examples; long-acting depot products can have intervals measured in months.
Convenience, product availability and response matter. A longer ester is not a promise of more muscle gain, and a shorter one is not automatically better.
Same released hormone Testosterone
Propionate Shorter-acting preparation ↗ Enanthate / cypionate Weekly IM examples in treatment guidance ↗ Injected undecanoate Long intervals in named depot products ↗ Sustanon Several esters combined in one product ↗
Published treatment schedules
Weekly / 2-weekly
Cypionate or enanthate: guideline
75–100 mg IM weekly, or 150–200 mg every two weeks, as starting examples.
Every 3–6 weeks
Alliance enantate: maintenance
250 mg IM in the UK label. Its initial interval is two to three weeks; other products differ.
Every 10–14 weeks
Nebido: maintenance
1,000 mg IM in the UK label. The initial loading interval can be shorter.
Sources: Endocrine Society guideline, Alliance label and Nebido label. These are ongoing prescribed-treatment examples, not bodybuilding cycles or equivalent amounts. Product-specific instructions and follow-up govern treatment.
Propionate is a shorter-acting option, but a generic ester name cannot supply a universal prescription. Sustanon combines four esters; oral undecanoate is a different preparation from the long-acting injection.
How an ester changes delivery
One hormone, several delivery steps
-
Esterified testosterone
The stated ester mass includes the attached chemical group.
-
Release from the preparation
Oil, route, site and formulation affect absorption.
-
Ester cleavage
Testosterone is separated from the ester group.
-
Hormone disposition
The released testosterone is distributed and metabolized.
Why half-life tables disagree
Half-life must describe what is declining and which preparation was studied. A depot can keep releasing drug while circulating hormone is being removed. A release half-life and a circulating elimination half-life are therefore not automatically interchangeable.
Read the source-specific half-life figures
| Source-specific preparation | Reported value | Read it as |
|---|---|---|
| Alliance testosterone enantate, IM oil | 2–3 days | Blood half-life stated for healthy volunteers |
| Depo-Testosterone cypionate, IM | About 8 days | Approximate label value for this route |
| Nebido undecanoate, IM depot | 90 ± 40 days | A depot-release parameter, not a negative-test deadline |
Sources: Alliance SmPC, Depo-Testosterone label and Nebido SmPC. These are not results from a single head-to-head trial or recommended injection intervals.
Why ester milligrams and testosterone milligrams differ
Some of an ester molecule’s mass belongs to the attached ester rather than testosterone. The longer/heavier group does not create extra hormone. Product labels may state both the ester amount and its testosterone equivalent; those are two ways to describe chemical content.
The distinction is visible in Sustanon 250: its named formula contains 250 mg of combined esters corresponding to 176 mg of testosterone. That does not mean the product has 70.4% clinical bioavailability. It is molecular accounting. Sustanon composition
Even equal testosterone-equivalent masses do not prove equal blood profiles or clinical interchangeability, because absorption and the regimen still matter.
Route and product are part of the model
An intramuscular oil injection and a subcutaneous autoinjector should not share parameters merely because both contain enanthate. Human research has evaluated those preparations separately. Enanthate formulation study
Cypionate also has a ring-containing ester, so “one extra carbon” is incomplete shorthand for its difference from straight-chain enanthate. The exact structure is useful chemistry; it is not a shortcut to predicting a person’s response.
What to compare in the tool
Use the comparison tool for a defined question, such as how a stated release assumption changes overlap. Keep the model, units, total amount and observation window visible. If several variables change, the result cannot be attributed to ester alone.
A testosterone curve from entered injections may exclude endogenous production. It must not be compared directly with total-testosterone lab ranges or used to choose a PCT threshold. Methodology explains that output boundary.
Common questions
Is enanthate or cypionate inherently better? A product’s convenience, tolerability and measured clinical response matter; the ester name alone cannot answer.
Does longer release mean higher benefit? No. Release duration and clinical outcome are separate measurements.
Does half-life show detection or fertility recovery? Neither. Read testing methods and PCT fundamentals for those separate questions.
Sources and review notes
Checked October 12, 2026. The schedule facts describe named label or guideline examples; they are not interchangeable prescriptions. Nebido’s depot-release parameter is different from a circulating-hormone half-life. The linked enanthate study evaluated IM and SC preparations separately. The opening map groups product choices without claiming a matched potency or safety ranking.
Related compounds & model context
Article citations are linked in the text. Related catalog entries have separate model inputs and source notes, which may include unverified estimates. See our methodology for model assumptions and limitations.